Literature DB >> 32891487

How I do it - Second stage revision total knee arthroplasty.

Benjamin Bloch1.   

Abstract

BACKGROUND: Infection is a potentially devastating complication following primary total knee arthroplasty, and the traditional gold-standard treatment for chronic prosthetic joint infection has been in the form of a two-stage revision total knee arthroplasty. This involves a first stage - removal of all implants and infected material, with implantation of a temporary spacer - followed by a second stage which includes reimplantation with a definitive prosthesis. INDICATIONS: Although the outcomes of single-stage and two-stage revision arthroplasty surgeries are similar, there are certain indications such as atypical or more virulent organisms, patient factors and soft tissue factors that would favour a two-stage approach. SURGICAL TECHNIQUE: The second stage revision procedure consists of explantation of the spacer with a debridement and synovectomy. Further samples are sent for microbiological analysis. Once the surgical field is clean and lavaged, the definitive prosthesis is implanted.
CONCLUSIONS: A second stage revision total knee arthroplasty is a reliable procedure for the treatment of chronic prosthetic joint infection. There is a significant re-revision rate, predominantly due to recurrent deep infection. Crown
Copyright © 2020. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Infection; Prosthetic joint infection; Revision total knee arthroplasty; Second stage

Mesh:

Substances:

Year:  2020        PMID: 32891487     DOI: 10.1016/j.knee.2020.08.012

Source DB:  PubMed          Journal:  Knee        ISSN: 0968-0160            Impact factor:   2.199


  1 in total

1.  Should synovectomy be performed during total knee arthroplasty for knee osteoarthritis: A protocol for systematic review and meta-analysis.

Authors:  Mingchao Li; Xiaoqing Shi; Songjiang Yin; Li Zhang; Peng Wu; Taiyang Liao; Lishi Jie; Peimin Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.